PHARMACEUTICAL FORMULATIONS OF AN AMYLIN RECEPTOR AGONIST AND A GLP-1 RECEPTOR AGONIST COMPRISING A CYCLODEXTRIN

PE0013042026A1Pending Publication Date: 2026-07-02NOVO NORDISK AS

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: PE2025003094
Authority / Receiving Office: PE · PE
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-06-14
Filing Date: 2024-06-14
Publication Date: 2026-07-02

Application Information

Patent Timeline

14 Jun 2024

Priority

14 Jun 2024

Application

PE2025003094

02 Jul 2026

Publication

PE0013042026A1

IPC: A61K9/00; A61K38/00; A61K38/22; A61K38/26; A61K47/40; A61P3/10; A61P9/00; A61P25/28

CPC: A61K9/0019; A61K38/26; A61K38/22; A61K47/40; A61P3/10; A61P9/00; A61K2300/00; A61P3/04

Inventors: KJELDSEN Benjamin Troest; HANSEN Rosa Rebecca Erritzøe

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

A preserved liquid pharmaceutical formulation is described comprising an amylin receptor agonist, a GLP-1 receptor agonist, and a cyclodextrin comprising hydroxypropyl substitutions and one or more preservatives. This co-formulation can be used for the medical treatment of overweight or obese subjects, with or without associated comorbidities; diabetes, with or without associated comorbidities; and cardiovascular diseases.

Need to check novelty before this filing date? Find Prior Art